CLDI (Calidi Bio) רווחיות מכירות גולמית

Calidi Biotherapeutics owns a proprietary virotherapy delivery platform, which enables the company to exercise pricing power. The development of its R&D ecosystem depends on FDA approvals and venture capital investments. Realization margins on the GURU.Markets service chart show that 0.00 represents the latest level value. Demand for cancer treatment is non-cyclical, providing the business with high macroeconomic resilience.
פילוחי מדדים פיננסיים ומדדי שוק עבור Calidi Biotherapeutics (CLDI)

Gross margin determines the portion of revenue remaining after paying direct production costs. In fundamental analysis, this ratio measures cost management efficiency and the business's ability to generate profit from each unit of product. By analyzing historical gross margins, an investor can assess the operational resilience of Calidi Biotherapeutics (CLDI) in developing high-tech oncolytic virotherapy drugs based on stem cells.